Nasdaq · CIK 0001815442
KYMR Kymera Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $112.40 on Oct 9, 2026, +101% from the 52-week low and -12% from the high.
Last 90 days
Net insider value
-$4.2M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$4.2M by 2 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
KYMROct 9, 2026 · close 112.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Kymera Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Nello Mainolfi Chief Executive Officer sell | $3.4M 30,000 shares | -4% | +101% from low-14% from high | |
| 41Moderate | Brian Adams Chief Legal Officer sell | $744k 6,371 shares | -11% | - | |
| 55Moderate | Bvf Partners L P/il director, other buy | $14M 317,167 shares | +12% | +107% from low-17% from high | |
| 62Notable | Baker Bros. Advisors LP director buy | $29M 655,500 shares | +137% | +107% from low-17% from high | |
| 27Weak | Elena Ridloff director sell | $225k 4,500 shares | -100% | +130% from low-8% from high | |
| 29Weak | Jeffrey W. Albers director sell | $311k 6,349 shares | -100% | +107% from low-17% from high | |
| 28Weak | Pamela Esposito director sell | $245k 5,000 shares | -100% | +107% from low-17% from high | |
| 30Weak | Nello Mainolfi Chief Executive Officer sell | $1.5M 30,000 shares | -4% | +107% from low-17% from high | |
| 34Weak | Elena Ridloff director sell | $553k 12,000 shares | -100% | +107% from low-17% from high | |
| 43Moderate | Jeremy G Chadwick Chief Operating Officer sell | $75k 2,575 shares | -4% | +40% from low-44% from high | |
| 41Moderate | Jeremy G Chadwick Chief Operating Officer sell | $42k 1,383 shares | -2% | - | |
| 38Weak | Ellen Chiniara Chief Legal Officer sell | $68k 2,241 shares | -3% | - | |
| 41Moderate | Jared Gollob Chief Medical Officer sell | $175k 5,740 shares | -5% | - | |
| 49Moderate | Bruce N. Jacobs Chief Financial Officer sell | $214k 7,035 shares | -3% | - | |
| 26Weak | Ellen Chiniara Chief Legal Officer sell | $131k 3,129 shares | -5% | - | |
| 10Weak | Pamela Esposito director sell | $123k 2,500 shares | -100% | - |
Transactions
The last 76 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Nello Mainolfi Chief Executive Officer | MOption exercise Common Stock10b5-1 | +30,000 | $2.08 | $62k | 696,568 | 11 d ago |
| Oct 1, 2026 | Nello Mainolfi Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -3,525 | $111.44 | $393k | 693,043 | 11 d ago |
| Oct 1, 2026 | Nello Mainolfi Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -5,506 | $112.42 | $619k | 687,537 | 11 d ago |
| Oct 1, 2026 | Nello Mainolfi Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -4,876 | $113.24 | $552k | 682,661 | 11 d ago |
| Oct 1, 2026 | Nello Mainolfi Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -7,601 | $114.43 | $870k | 675,060 | 11 d ago |
| Oct 1, 2026 | Nello Mainolfi Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -8,230 | $115.40 | $950k | 666,830 | 11 d ago |
| Oct 1, 2026 | Nello Mainolfi Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -262 | $116.12 | $30k | 666,568 | 11 d ago |
| Oct 1, 2026 | Nello Mainolfi Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 60,000 | 11 d ago |
| Sep 4, 2026 | Brian Adams Chief Legal Officer | SOpen-market sale Common Stock | -1,209 | $115.55 | $140k | 55,416 | 38 d ago |
| Sep 4, 2026 | Brian Adams Chief Legal Officer | SOpen-market sale Common Stock | -3,025 | $116.81 | $353k | 52,391 | 38 d ago |
| Sep 4, 2026 | Brian Adams Chief Legal Officer | SOpen-market sale Common Stock | -2,137 | $117.57 | $251k | 50,254 | 38 d ago |
| Sep 3, 2025 | Brian Adams Chief Legal Officer | AGrant or award Common Stock | +52,500 | $0.00 | $0 | 52,500 | Sep 3, 2025 |
| Sep 3, 2025 | Brian Adams Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Sep 3, 2025 |
| Jun 30, 2025 | Bvf Partners L P/il director, other | POpen-market purchase Common Stock, $0.0001 par value | +142,604 | $44.00 | $6.3M | 2,798,795 | Jul 1, 2025 |
| Jun 30, 2025 | Bvf Partners L P/il director, other | POpen-market purchase Common Stock, $0.0001 par value | +115,783 | $44.00 | $5.1M | 2,219,858 | Jul 1, 2025 |
| Jun 30, 2025 | Bvf Partners L P/il director, other | POpen-market purchase Common Stock, $0.0001 par value | +58,780 | $44.00 | $2.6M | 353,412 | Jul 1, 2025 |
| Jun 25, 2025 | Bvf Partners L P/il director, other | AGrant or award Stock Option (Right to Buy)derivativeindirect: See footnote | +16,000 | $0.00 | $0 | 16,000 | Jul 1, 2025 |
| Jun 30, 2025 | Baker Bros. Advisors LP director | POpen-market purchase Common Stockindirect: See Footnotes | +55,191 | $44.00 | $2.4M | 534,134 | Jun 30, 2025 |
| Jun 30, 2025 | Baker Bros. Advisors LP director | POpen-market purchase Common Stockindirect: See Footnotes | +600,309 | $44.00 | $26M | 6,117,295 | Jun 30, 2025 |
| Jun 30, 2025 | Baker Bros. Advisors LP director | POpen-market purchase Prefunded Warrantsderivativeindirect: See Footnotes | +55,191 | $44.00 | $2.4M | 974,192 | Jun 30, 2025 |
| Jun 30, 2025 | Baker Bros. Advisors LP director | POpen-market purchase Prefunded Warrantsderivativeindirect: See Footnotes | +600,309 | $44.00 | $26M | 10,225,962 | Jun 30, 2025 |
| Jun 25, 2025 | Baker Bros. Advisors LP director | AGrant or award Non-Qualified Stock Option (right to buy)derivativeindirect: See Footnotes | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 25, 2025 | Jeffrey W. Albers director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 25, 2025 | Bruce Booth director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 25, 2025 | Pamela Esposito director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 25, 2025 | Gorjan Hrustanovic director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 25, 2025 | Elena Ridloff director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 25, 2025 | Victor Sandor director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 25, 2025 | John Maraganore director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 25, 2025 | Baker Bros. Advisors LP director | AGrant or award Non-Qualified Stock Option (right to buy)derivativeindirect: See Footnotes | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 11, 2025 | Elena Ridloff director | MOption exercise Common Stock10b5-1 | +4,500 | $20.29 | $91k | 4,500 | Jun 11, 2025 |
| Jun 11, 2025 | Elena Ridloff director | SOpen-market sale Common Stock10b5-1 | -4,500 | $50.00 | $225k | 0 | Jun 11, 2025 |
| Jun 11, 2025 | Elena Ridloff director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,500 | $0.00 | $0 | 4,500 | Jun 11, 2025 |
| Jun 3, 2025 | Jeffrey W. Albers director | MOption exercise Common Stock10b5-1 | +6,349 | $10.34 | $66k | 6,349 | Jun 3, 2025 |
| Jun 3, 2025 | Pamela Esposito director | MOption exercise Common Stock10b5-1 | +5,000 | $29.55 | $148k | 5,000 | Jun 3, 2025 |
| Jun 3, 2025 | Nello Mainolfi Chief Executive Officer | MOption exercise Common Stock10b5-1 | +30,000 | $2.08 | $62k | 690,482 | Jun 3, 2025 |
| Jun 3, 2025 | Elena Ridloff director | MOption exercise Common Stock10b5-1 | +12,000 | $27.67 | $332k | 12,000 | Jun 3, 2025 |
| Jun 3, 2025 | Jeffrey W. Albers director | SOpen-market sale Common Stock10b5-1 | -6,349 | $49.00 | $311k | 0 | Jun 3, 2025 |
| Jun 3, 2025 | Pamela Esposito director | SOpen-market sale Common Stock10b5-1 | -5,000 | $49.04 | $245k | 0 | Jun 3, 2025 |
| Jun 3, 2025 | Nello Mainolfi Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -30,000 | $49.00 | $1.5M | 660,482 | Jun 3, 2025 |
| Jun 3, 2025 | Elena Ridloff director | SOpen-market sale Common Stock10b5-1 | -7,200 | $45.50 | $328k | 4,800 | Jun 3, 2025 |
| Jun 3, 2025 | Elena Ridloff director | SOpen-market sale Common Stock10b5-1 | -4,800 | $47.00 | $226k | 0 | Jun 3, 2025 |
| Jun 3, 2025 | Pamela Esposito director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 24,127 | Jun 3, 2025 |
| Jun 3, 2025 | Jeffrey W. Albers director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,349 | $0.00 | $0 | 5,000 | Jun 3, 2025 |
| Jun 3, 2025 | Nello Mainolfi Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 465,559 | Jun 3, 2025 |
| Jun 3, 2025 | Elena Ridloff director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,000 | $0.00 | $0 | 0 | Jun 3, 2025 |
| May 23, 2025 | Jeremy G Chadwick Chief Operating Officer | SOpen-market sale Common Stock | -2,575 | $29.30 | $75k | 66,420 | May 23, 2025 |
| Apr 8, 2025 | Noah Goodman Chief Business Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 50,081 | Apr 9, 2025 |
| Apr 8, 2025 | Noah Goodman Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 9, 2025 |
| Mar 31, 2025 | Bruce N. Jacobs Chief Financial Officer | MOption exercise Common Stock | +25,000 | $2.08 | $52k | 226,886 | Apr 1, 2025 |
| Mar 31, 2025 | Bruce N. Jacobs Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 69,899 | Apr 1, 2025 |
| Mar 3, 2025 | Jared Gollob Chief Medical Officer | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 125,740 | Mar 3, 2025 |
| Mar 3, 2025 | Nello Mainolfi Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +365,000 | $0.00 | $0 | 365,000 | Mar 3, 2025 |
| Mar 3, 2025 | Bruce N. Jacobs Chief Financial Officer | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 208,921 | Mar 3, 2025 |
| Mar 3, 2025 | Ellen Chiniara Chief Legal Officer | AGrant or award Common Stock | +27,500 | $0.00 | $0 | 82,326 | Mar 3, 2025 |
| Mar 3, 2025 | Jeremy G Chadwick Chief Operating Officer | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 69,183 | Mar 3, 2025 |
| Mar 3, 2025 | Ellen Chiniara Chief Legal Officer | SOpen-market sale Common Stock | -1,833 | $30.33 | $56k | 80,493 | Mar 3, 2025 |
| Mar 3, 2025 | Bruce N. Jacobs Chief Financial Officer | SOpen-market sale Common Stock | -5,754 | $30.33 | $175k | 203,167 | Mar 3, 2025 |
| Mar 3, 2025 | Jeremy G Chadwick Chief Operating Officer | SOpen-market sale Common Stock | -1,131 | $30.33 | $34k | 68,052 | Mar 3, 2025 |
| Mar 3, 2025 | Jared Gollob Chief Medical Officer | SOpen-market sale Common Stock | -4,695 | $30.33 | $142k | 121,045 | Mar 3, 2025 |
| Mar 3, 2025 | Bruce N. Jacobs Chief Financial Officer | SOpen-market sale Common Stock | -1,281 | $31.00 | $40k | 201,886 | Mar 3, 2025 |
| Mar 3, 2025 | Jared Gollob Chief Medical Officer | SOpen-market sale Common Stock | -1,045 | $31.00 | $32k | 120,000 | Mar 3, 2025 |
| Mar 3, 2025 | Jeremy G Chadwick Chief Operating Officer | SOpen-market sale Common Stock | -252 | $31.00 | $7,813 | 67,800 | Mar 3, 2025 |
| Mar 3, 2025 | Ellen Chiniara Chief Legal Officer | SOpen-market sale Common Stock | -408 | $31.00 | $13k | 80,085 | Mar 3, 2025 |
| Mar 3, 2025 | Jared Gollob Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Mar 3, 2025 |
| Mar 3, 2025 | Ellen Chiniara Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Mar 3, 2025 |
| Mar 3, 2025 | Jeremy G Chadwick Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 3, 2025 |
| Mar 3, 2025 | Bruce N. Jacobs Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Mar 3, 2025 |
| Jan 10, 2025 | Bruce N. Jacobs Chief Financial Officer | MOption exercise Common Stock | +10,000 | $2.08 | $21k | 178,921 | Jan 13, 2025 |
| Jan 10, 2025 | Nello Mainolfi Chief Executive Officer | MOption exercise Common Stock | +10,000 | $2.08 | $21k | 659,959 | Jan 13, 2025 |
| Jan 10, 2025 | Bruce N. Jacobs Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 94,899 | Jan 13, 2025 |
| Jan 10, 2025 | Nello Mainolfi Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 495,559 | Jan 13, 2025 |
| Jan 6, 2025 | Ellen Chiniara Chief Legal Officer | SOpen-market sale Common Stock | -3,129 | $41.75 | $131k | 54,826 | Jan 6, 2025 |
| Dec 2, 2024 | Pamela Esposito director | MOption exercise Common Stock10b5-1 | +2,500 | $29.55 | $74k | 2,500 | Dec 2, 2024 |
| Dec 2, 2024 | Pamela Esposito director | SOpen-market sale Common Stock10b5-1 | -2,500 | $49.00 | $123k | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Pamela Esposito director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,500 | $0.00 | $0 | 29,127 | Dec 2, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Brian AdamsChief Legal Officer
- Jeffrey W. Albersdirector
- Baker Bros. Advisors LPdirector, owner, other
- Bvf Partners L P/ilother, owner, director
- Bruce Boothdirector
- Jeremy G ChadwickChief Operating Officer
- Ellen ChiniaraChief Legal Officer
- Pamela Espositodirector
- Jared GollobChief Medical Officer
- Noah GoodmanChief Business Officer
- Gorjan Hrustanovicdirector
- Bruce N. JacobsChief Financial Officer
- John Maraganoredirector
- Nello MainolfiChief Executive Officer
- Elena Ridloffcfo, officer, director
- Victor Sandordirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.